)
Visual21 Nov 2025
Data center suppliers
Prelude Therapeutics (PRLD) investor relations material
Prelude Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Strategic refocus on R&D and capital allocation to advance lead oncology programs: JAK2 V617F selective inhibitor and KAT6A selective degrader, both targeting validated pathways and expected to enter the clinic in 2026.
Expanded collaborations with Incyte and AbCellera, including an exclusive option agreement for JAK2 V617F and new licensing payments.
Paused SMARCA2 clinical program and reduced workforce to prioritize resources.
Preclinical data from JAK2 V617F and CALR-targeted DAC programs accepted for oral presentations at major conferences.
Financial highlights
Secured $60 million upfront from Incyte: $35 million cash and $25 million equity investment at $4/share.
Potential for up to $910 million in total payments from Incyte, including $100 million on option exercise, $775 million in milestones, and single-digit royalties.
Revenue for Q3 2025 was $6.5 million, up from $3.0 million in Q3 2024, driven by collaboration amendments.
Net loss for Q3 2025 was $19.7 million ($0.26 per share), improved from $32.3 million ($0.43 per share) in Q3 2024.
Cash, cash equivalents, restricted cash, and marketable securities totaled $58.2 million as of September 30, 2025.
Outlook and guidance
Cash runway projected to support operations and clinical development into 2027, but substantial doubt remains about ability to fund operations for the next twelve months due to program changes and uncertainties.
IND filing for JAK2 V617F program planned for Q1 2026, with phase one trial initiation in H1 2026.
KAT6A degrader IND filing expected mid-2026, with phase one trial start in H2 2026; clinical data updates likely in 2027.
Plans to seek additional funding through equity, debt, collaborations, or licensing.
Key JAK2 data for Incyte option decision
Confirm KAT6A safety differentiation in clinic
Next major pipeline value inflection points
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Prelude Therapeutics earnings date
Q4 202513 Mar, 2026
Next Prelude Therapeutics earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Prelude Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, small molecule therapies targeting key drivers of cancer cell growth and resistance. Leveraging its expertise in cancer biology, medicinal chemistry, and drug development, Prelude Therapeutics is committed to advancing a pipeline of innovative treatments aimed at addressing the complex challenges of cancer treatment. The company is headquartered in Wilmington, Delaware, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage